The short answer
Adequate vitamin D is part of risedronate treatment, with supplementation when intake is inadequate. Vitamin D alone should not be described as a proven mineral-binding interaction. Timing depends on the risedronate formulation and whether the supplement also contains calcium or other minerals.
What this answer covers
Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here.
- Supplement or preparation
- Vitamin D
- Medication ingredient
- risedronate
Why does this combination need attention?
Both labels recommend calcium and vitamin D supplementation when intake is inadequate and correction of low calcium or other mineral disorders before treatment. All participants in the delayed-release trial received calcium and vitamin D at another meal. That design does not isolate the benefit or absorption effect of vitamin D alone.
How should the doses be scheduled?
Standard risedronate is taken before breakfast and oral vitamins, with at least the initial 30-minute fast. Atelvia is taken immediately after breakfast. A vitamin D product containing calcium, magnesium or iron should follow the separate-time instructions for those minerals. Mineral-free vitamin D is not established as having the same binding interaction; confirm its schedule with the pharmacist.
What should I discuss with my pharmacist?
Discuss usual intake, existing supplements and known deficiency or malabsorption with your clinician. The goal is adequate nutrition, not automatically adding a high dose. Bring combination-product labels because a product marketed mainly as vitamin D may also contain calcium. The prescribed risedronate dose and dosing day should not be changed independently.
What are the limits of the evidence?
A study of a calcium-vitamin D tablet cannot prove that vitamin D caused its absorption effect. These sources do not establish a universal vitamin D amount, show that all D2 or D3 products interfere with risedronate, or transfer the calcium interaction to mineral-free vitamin D. Clinical needs and the exact supplement formula determine the plan.
Evidence and practical considerations
Timing & monitoring
Adequate vitamin D is part of risedronate treatment, with supplementation when intake is inadequate. Vitamin D alone should not be described as a proven mineral-binding interaction. Timing depends on the risedronate formulation and whether the supplement also contains calcium or other minerals.
- Exact scope
- Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here. with oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Medication form and route
- oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Timing or duration
- Timing applies on each prescribed oral dose day. Nutrient adequacy is an ongoing treatment consideration. Clinical trial durations and limitations are recorded in each source.
What remains uncertain
- A study of a calcium-vitamin D tablet cannot prove that vitamin D caused its absorption effect. These sources do not establish a universal vitamin D amount, show that all D2 or D3 products interfere with risedronate, or transfer the calcium interaction to mineral-free vitamin D. Clinical needs and the exact supplement formula determine the plan.
Factors that may matter: Medication route and release formulation; Supplement mineral content and chemical preparation; Timing relative to breakfast and other oral products; Dietary intake and pre-existing mineral or vitamin deficiency.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients taking immediate-release oral risedronate sodium tablets for approved bone indications.
The medicine is taken before breakfast and other oral products with an initial 30-minute interval. Calcium, antacids, magnesium products and iron are scheduled at a different time of day. Calcium and vitamin D adequacy is recommended, with supplementation if dietary intake is inadequate.
How this applies: Supports adequate vitamin D intake and product-specific timing. Calcium-vitamin D combination evidence does not establish that vitamin D alone binds the medicine. Exact scope: Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here.
Product instructions and class-based absorption precautions do not quantify every individual mineral salt. They must not be substituted for delayed-release dosing instructions.
Source 2: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women receiving delayed-release oral risedronate 35 mg; absorption crossover included 101 postmenopausal women.
Co-administration of the combination supplement reduced risedronate exposure approximately 38%. The label places calcium, antacids, magnesium products and iron at a different time of day and specifies Atelvia immediately after breakfast.
How this applies: Supports adequate vitamin D intake and product-specific timing. Calcium-vitamin D combination evidence does not establish that vitamin D alone binds the medicine. Exact scope: Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here.
The absorption study used a combined calcium-vitamin D product and cannot isolate vitamin D, another mineral or every calcium salt. The 38% estimate is not transferable to all formulations or supplements.
Source 3: peer-reviewed randomized clinical trial
europepmc.org · Source check Sep 10, 2026
Population: 922 treated postmenopausal women with osteoporosis; immediate-release daily group n=307, delayed-release before-breakfast n=308 and after-breakfast n=307.
Delayed-release regimens were non-inferior on lumbar-spine bone mineral density. The supplement instructions deliberately separated calcium and vitamin D from risedronate.
How this applies: Direct evidence for risedronate formulation schedules, with separated calcium/vitamin D use. It does not test simultaneous vitamin d co-administration. Exact scope: Vitamin D intake or oral supplementation during oral risedronate therapy. Plain vitamin D and calcium-vitamin D products are distinguished; exact D2 and D3 dose equivalence is not established here.
Formulation efficacy study, not a simultaneous mineral co-administration trial. All subjects received supplements; their necessity, independent effects and optimal individual doses were not randomized. The older before-breakfast trial arm does not override current Atelvia after-breakfast instructions.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current oral formulation labels, route boundaries and original dosing evidence assessed. Exact existing statements adjudicated and article prepared. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: c12e7718197db5e0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.